Max Planck Institute to Use Waters Synapt HDMS to Study Protein Role in Brain Disease | GenomeWeb
NEW YORK (GenomeWeb News) - The Max Planck Institute of Biochemistry recently received one of Waters' mass spec systems, the Milford, Mass.-based company said Friday.
 
The Department of Cellular Biochemistry at the Martinsried, Germany-based institute will use the Synapt High Definition MS system to study the role of proteins in brain-wasting diseases such as Huntington's disease.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.